Graybug Vision Appoints Robert Breuil as Chief Financial Officer

Graybug Vision announced the appointment of Robert S. Breuil as chief financial officer, effective immediately. Mr. Breuil succeeds Daniel Geffken, founder and managing director of Danforth Advisors, who led the function as ad-interim CFO.

“I am excited to welcome Robert Breuil to the Graybug team. His extensive leadership experience working in several small-cap biopharmaceutical companies will add great value as we advance our clinical development programs in retinal diseases and glaucoma,” Fred Guerard, Chief Executive Officer, Graybug Vision, said in a company news release. “I also would like to thank Daniel Geffken for his significant contributions over the past months.”

Mr. Breuil has over 20 years of experience in the biopharmaceutical and drug delivery industries, serving exclusively as CFO since 2003. Prior to joining Graybug Vision, he was the CFO of Corium International, a commercial-stage biopharmaceutical company, for 7 years, taking the company from private to public and then through the sale to a private equity buyer. Prior to that, he was the CFO of Codexis, a developer of biocatalysts for the pharmaceutical and fine chemical production industries for three and a half years. In 2002, he became the CFO of Aerogen, a specialty pharmaceutical company focusing on the field of aerosolized drug delivery, which was acquired by Nektar Therapeutics in 2005.